Contact lenses

Food and Drug Administration (FDA) for its adjustable gastric band, an implantable device for the treatment of morbid obesity.Worldwide Pharmaceutical sales of $6.2 billion for the first quarter represented an increase over the prior year of 10.6% with operational growth of 8.6% and a positive impact from currency of 2.0%.

Domestic sales increased 9%, while international sales increased 13.6% (7.7% from operations and 5.9% from currency).Sales growth reflects the strong performance of TOPAMAX®, an antiepileptic and a treatment for the prevention of migraine headaches; LEVAQUIN®, an anti-infective, and our antipsychotic franchise, which includes RISPERDAL® , RISPERDAL® CONSTA® and INVEGA®.During the quarter, the European Commissiongranted conditional marketing authorization for PREZISTA™, a protease inhibitor for the treatment of HIV-1 infected patients.

In addition, the FDA granted pediatric exclusivity for both LEVAQ...

Read more...